OncoVista公司L-核苷共轭药物OVI-117研究性新药申请获FDA批准

作者：potato来源：生物谷2012-7-11 2012年7月10日，OncoVista创新疗法公司（OncoVista Innovative Therapies Inc）周二宣布，L-核苷共轭药物（OVI-117）研究性新药申请已获FDA批准。OncoVista是一家生物制药公司，主要从事于癌症靶向性疗法的开发及商业化。该公司称，L-核苷共轭药物（OVI-117）是一种胸苷酸合成酶抑制剂，具有强化的药理特性，保留有疗效的同时降低了药物的毒性。该药在结直肠癌、乳腺癌、胃癌、前列腺癌治疗方面尤具潜力。 OncoVista董事长、总裁兼CEO Alexander Weis博士称："FDA对公司IND的迅速批准，加强了OncoVista成为更有效更低毒靶向性癌症疗法开发领域领导者的使命感。"（生物谷bioon.com）

About OVI-117  OVI-117, a derivative of FdUMP/5-FU, is a Thymidylate Synthase (TS) inhibitor with enhanced pharmacological properties resulting in the retention of efficacy and the reduction of toxicity. It has particular promise for colon, breast, gastric and prostate tumors.

About OncoVista Innovative Therapies Texas-based OncoVista Innovative Therapies, Inc., founded in 2004, is a biopharmaceutical company engaged in the development and commercialization of targeted cancer therapies which are more efficacious and less toxic. For additional information, please visit OncoVista's corporate website at www.oncovista.com